Biotechnology company creating psychedelic supply chain through research, extraction, formulation and delivery of psychedelics HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) announced having successfully exported naturally extracted psilocybin from its facility in Jamaica to the United States.
The company has operations in Jamaica in form of strategic partnerships with P.A Benjamin Manufacturing Company and Hypha Wellness to provide cultivation and processing facilities for magic mushrooms which are used to extract psilocybin for authorized research purposes.
Importation of naturally extracted psilocybin into California was given a nod after Mycrodose Therapeutics, HAVN’s supply partner was granted an import license by the United States Drug Enforcement Administration (DEA).
According to the partnership agreement, Mycrodose will be serving as a distributor of HAVN’s naturally extracted psilocybin across the United States a move which will allow HAVN Life Sciences to meet the multiple supply agreements it currently has in place.
“With their track-record of working with the U.S. Food and Drug Administration (FDA), a proven track record of core business fundamentals, and registration with the DEA, Mycrodose Therapeutics is an ideal supply partner for HAVN Life. Having a supply partner that gives us access to the rapidly growing U.S. market for research purposes is absolutely key for us as we look to expand our business in 2022,” said the chief executive of HAVN Life Sciences, Tim Moore.
